Skip to content

Surgery Partners, Inc. SGRY Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs

Other financials

Income statement

See full
Revenue$810.9M+4.5%
Operating income$65.8M+6.3%
Net income-$35.9M+4.8%
EPS (diluted)-$0.28+6.7%

Balance sheet

See full
Cash & equivalents$182.3M-20.5%
Total debt$5.1B+4.6%
Total equity$1.7B-3.0%
Total assets$8.0B+1.2%

Cash flow

See full
Operating cash flow$11.7M+95.0%
CapEx$16.0M-29.5%
Free cash flow-$4.3M+74.3%

Valuation

See full
Market cap$1.99B-49.1%

Profitability

See full
Gross margin23.1%
Operating margin11.8%+1.2pp
Net margin-2.3%-0.9pp
FCF margin6.2%+0.8pp

Returns & leverage

See full
Return on equity-4.4%-1.6pp
Debt / equity+0.2×
Current ratio1.9×0.0×

Where this comes from

Reported directly by Surgery Partners, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts.

The official record: Surgery Partners, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Surgery Partners, Inc.'s deferred tax liabilities, deferred expense, debt issuance costs?
Surgery Partners, Inc. (SGRY) reported deferred tax liabilities, deferred expense, debt issuance costs of $4.7M in Q4 2025.